The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility.
China pharma shares fall as western rivals lead in vaccine trials
https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b
Successful trials of western pharmaceutical groups’ coronavirus vaccines have sliced more than $13bn off the market capitalisation of Chinese rivals, hitting Beijing’s ambitions to lead the global fight against the pandemic.
Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
The initial pipeline contains biosimilar candidates for treatment in the fields of autoimmunity, ophthalmology, and oncology, as well for treating severe immune and inflammatory conditions.
Pfizer and LianBio link up to bring new drugs to China
https://www.thepharmaletter.com/article/pfizer-and-lianbio-link-up-to-bring-new-drugs-to-china
LianBio’s aim is to catalyze the development and accelerate availability of ‘paradigm-shifting’ medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. It was founded by the privately-owned hedge fund sponsor Perceptive Advisors.
Novo Nordisk’s new Chinese-language chatbot for people with diabetes
It’s partnering with Microsoft to create a Chinese-language AI chatbot, set to launch early next year on the Danish drugmaker’s digital patient support platforms.
Genscript, Legend Biotech founder Fangliang Zhang arrested in China for suspected smuggling
Two months of “residential surveillance” have now been turned into an official arrest for Fangliang “Frank” Zhang, the founder of Chinese CDMO giant Genscript Biotech and its CAR-T subsidiary Legend Biotech.
Thermo Fisher to establish new pharma services facility in China
Thermo Fisher Scientific Inc. has signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022.
Korean company Huons signs USD 31.4 million deal to supply anesthesia to China
http://www.koreabiomed.com/news/articleView.html?idxno=9710
Huons Global said it has signed a 35 billion won ($31.4-million) deal with Health-MIUMIU, a Chinese dental company, for supplying local anesthesia lidocaine and epinephrine 1:100,000 injections.
